The effects of antidepressants in parkinson's disease: A meta-analysis

被引：20

作者：

Frisina, Pasquale G. ^{[1
,2
]}

Tenenbaum, Harriet R. ^{[3
]}

Borod, Joan C. ^{[4
,5
]}

机构：

[1] Jewish Home & Hosp, Dept Med Res, Leir Parkinsons Dis Program, Lifecar Syst, New York, NY 10025 USA

[2] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA

[3] Kingston Univ, Dept Psychol, Kingston upon Thames KT1 2EE, Surrey, England

[4] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA

[5] Grad Ctr City Univ New York, Flushing, NY 11367 USA

来源：

INTERNATIONAL JOURNAL OF NEUROSCIENCE | 2008年 / 118卷 / 05期

关键词：

depression; meta-analysis; Parkinson's disease; treatment;

D O I：

10.1080/00207450701239418

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

This study explored the therapeutic effect of antidepressants in Parkinson's disease (PD) using a meta-analysis. Altogether, 24 placebo-controlled trials qualified for inclusion and revealed that tricyclic antidepressants (TCAs) had a greater antidepressant effect relative to selective serotonin reuptake inhibitors (SSRIs), Qb(1) = 8.87, p < .01, and the mono-amine-oxidase inhibitor, selegiline, Qb(1) = 7.90, p < .01. Whereas TCAs produced a significant side effect profile (odds ratio = 3.07), adverse events were negligible with SSRIs (odds ratio = 1.83) and selegeline (odds ratio = 1.63). Antidepressants can be beneficial for patients with PD. However, the choice of antidepressants needs to take depressive symptomatologies into account while monitoring side effects.

引用

页码：667 / 682

页数：16

共 56 条

[1] SELEGILINE IN DENOVO PARKINSONIAN-PATIENTS - THE FRENCH SELEGILINE MULTICENTER TRIAL (FSMT) [J].

ALLAIN, H ;

COUGNARD, J ;

NEUKIRCH, HC .

ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 :73-78

[2]

ANDERSEN J, 1980, ACTA NEUROL SCAND, V62, P210

[3]

[Anonymous], 1984, Meta-analysis procedures for social research

[4]

CALEY CF, 1992, J CLIN PSYCHIAT, V53, P278

[5] Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms [J].

Ceravolo, R ;

Nuti, A ;

Piccinni, A ;

Dell'Agnello, G ;

Bellini, G ;

Gambaccini, G ;

Dell'Osso, L ;

Murri, L ;

Bonuccelli, U .

NEUROLOGY, 2000, 55 (08) :1216-1218

[6]

Cohen J., 1988, POWERSTATISTICALSCIE, DOI 10.4324/9780203771587

[7]

CUMMINGS JL, 1992, AM J PSYCHIAT, V149, P443

[8] EFFECTS OF SELEGILINE (DEPRENYL) ON COGNITION IN EARLY PARKINSONS-DISEASE [J].

DALRYMPLEALFORD, JC ;

JAMIESON, CF ;

DONALDSON, IM .

CLINICAL NEUROPHARMACOLOGY, 1995, 18 (04) :348-359

[9]

FISKE ST, 2001, ANNU REV PSYCHOL, V52, P59

[10]

Glass G.V., 1981, Meta-analysis in social research

← 1 2 3 4 5 6 →